SEC Company Response from NextCure, Inc. (NXTC) (CIK 0001661059) (NXTC) — Nov 12, 2019
NextCure, Inc. (NXTC) (CIK 0001661059)
Date: Nov. 12, 2019 · CIK: 0001661059 · Accession: 0001104659-19-062669
AI Filing Summary & Sentiment
File numbers found in text: 333-234639
Show Raw Text
CORRESP 1 filename1.htm NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 November 12, 2019 VIA EDGAR U.S. Securities and Exchange Commission Office of Healthcare and Insurance Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NextCure, Inc. Registration Statement on Form S-1 File No. 333-234639 Acceleration Request Requested Date: Thursday, November 14, 2019 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), NextCure, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) to become effective on November 14, 2019, at 5:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Company may orally request by telephone. The Company hereby authorizes William Intner and Nick Hoover of Hogan Lovells US LLP, counsel to the Company, to make such request on its behalf. In making this request, the Company acknowledges that it is aware of its responsibilities under the Act. Please direct any questions or comments concerning this request to Mr. Intner at (410) 659-2778, and once the Registration Statement has been declared effective, please notify Mr. Intner by calling him at the same phone number. Very truly yours, NextCure, Inc. /s/ Steven P. Cobourn By: Steven P. Cobourn Title: Chief Financial Officer